Emerging pharmacotherapeutic approaches for the management of sickle cell disease

References

• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
   PubMed Web of Science ®Google Scholar
• Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376:1561–1573.
   PubMed Web of Science ®Google Scholar
• Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956;178:792–794.
   PubMed Web of Science ®Google Scholar
• Marotta CA, Forget BG, Cohen-Solal M, et al. Nucleotide sequence analysis of coding and noncoding regions of human beta-globin mRNA. Progr Nucleic Acid Res Mol Biol. 1976;19:165–175.
   PubMedGoogle Scholar
• Pauling L, Itano H, Singer SJ, et al. Sickle cell anemia: a molecular disease. Science. 1949;110:543–548.
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Overview of sickle cell anemia pathophysiology. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International Publishing AG; 2016. p. 49–73.
   Google Scholar
• Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood. 1987;70:1245–1266.
   PubMed Web of Science ®Google Scholar
• Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci USA. 1989;86:3356–3360.
   PubMed Web of Science ®Google Scholar
• Hebbel RP, Boogaerts MA, Eaton JW, et al. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med. 1980;302:992–995.
   PubMed Web of Science ®Google Scholar
• Chien S, Usami S, Bertles JF. Abnormal rheology of oxygenated blood in sickle cell anemia. J Clin Invest. 1970;49:623–634.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127:750–760.
   PubMed Web of Science ®Google Scholar
• Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018;68:263–299.
   PubMed Web of Science ®Google Scholar
• Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2017;4:CD002202.
   PubMedGoogle Scholar
• Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79:17–25.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008;93:20–26.
   PubMed Web of Science ®Google Scholar
• Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol. 2014;166:165–176.
   PubMed Web of Science ®Google Scholar
• Hebbel RP. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am. 2014;28:181–198.
   PubMed Web of Science ®Google Scholar
• De Montalembert M, Wang W. Cerebrovascular complications in children with sickle cell disease. Handb Clin Neurol. 2013;113:1937–1943.
   PubMedGoogle Scholar
• Minniti CP, Delaney KM, Gorbach AM, et al. Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. Am J Hematol. 2014;89:1–6.
   PubMed Web of Science ®Google Scholar
• Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015;11:161–171.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37–47.
   PubMed Web of Science ®Google Scholar
• Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383–1389.
   PubMed Web of Science ®Google Scholar
• Hebbel RP, Yamada O, Moldow CF, et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980;65:154–160.
   PubMed Web of Science ®Google Scholar
• Zhang D, Xu C, Manwani D, et al. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127:801–809.
   PubMed Web of Science ®Google Scholar
• Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA. 2002;99:3047–3051.
   PubMed Web of Science ®Google Scholar
• Chweih H, Silva JAF, Ferreira Jr. WA, et al. Role for platelets in mediating neutrophil recruitment in tnf-α induced vaso-occlusive processes in animals with sickle cell anemia. Blood. 2017;130: 540 Abstract.
   Web of Science ®Google Scholar
• Zhang D, Frenette PS. Leukocytes in the vaso-occlusive process. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International Publishing AG; 2016. p. 91–107.
   Google Scholar
• Telfer P, Bahal N, Lo A, et al. Management of the acute painful crisis in sickle cell disease – a re-evaluation of the use of opioids in adult patients. Br J Haematol. 2014;166:157–164.
   PubMed Web of Science ®Google Scholar
• Detterich JA. Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: what should be our goals for transfusion therapy? Clin Hemorheol Microcirc. 2018;68:173–186.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Cohen AR, Garro J, et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Am J Hematol. 2012;87:221–223.
   PubMed Web of Science ®Google Scholar
• Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion. 1997;37:382–392.
   PubMed Web of Science ®Google Scholar
• Nichols FT, Jones AM, Adams RJ. Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial Doppler testing. J Neuroimaging. 2001;11:354–362.
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11.
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896–899.
   PubMed Web of Science ®Google Scholar
• Porter M. Rapid fire: sickle cell disease. Emerg Med Clin North Am. 2018;36:567–576.
   PubMed Web of Science ®Google Scholar
• Fortin PM, Hopewell S, Estcourt LJ. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2018;8:CD012082.
   PubMedGoogle Scholar
• Shenoy S, Angelucci E, Arnold SD, et al. Current results and future research priorities in late effects after hematopoietic stem cell transplantation (HCT) for children with sickle cell disease and thalassemia: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2017;23:552–561.
   PubMed Web of Science ®Google Scholar
• Cavazzana M, Antoniani C, Miccio A. Gene therapy for beta-hemoglobinopathies. Mol Ther. 2017;25:1142–1154.
   PubMed Web of Science ®Google Scholar
• Lidonnici MR, Ferrari G. Gene therapy and gene editing strategies for hemoglobinopathies. Blood Cells Mol Dis. 2018;70:87–101.
   PubMed Web of Science ®Google Scholar
• Antoniani C, Meneghini V, Lattanzi A, et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human beta-globin locus. Blood. 2018;131:1960–1973.
   PubMed Web of Science ®Google Scholar
• Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376:848–855.
   PubMed Web of Science ®Google Scholar
• King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123:3089–3094.
   PubMed Web of Science ®Google Scholar
• Arnold SD, Bhatia M, Horan J, et al. Haematopoietic stem cell transplantation for sickle cell disease – current practice and new approaches. Br J Haematol. 2016;174:515–525.
   PubMed Web of Science ®Google Scholar
• Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: an update. Cytotherapy. 2018;20:899–910.
   PubMed Web of Science ®Google Scholar
• Cokic VP, Andric SA, Stojilkovic SS, et al. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood. 2008;111:1117–1123.
   PubMed Web of Science ®Google Scholar
• Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111:231–239.
   PubMed Web of Science ®Google Scholar
• Costa FF, Fertrin KY. Clinical manifestations and treatment of adult sickle cell disease. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International Publishing AG; 2016. p. 285–318.
   Google Scholar
• Almeida CB, Souza LE, Leonardo FC, et al. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood. 2015;126:711–720.
   PubMed Web of Science ®Google Scholar
• Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74:652–656.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter study of hydroxyurea. Blood. 1997;89:1078–1088.
   PubMed Web of Science ®Google Scholar
• Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine (Baltimore). 1996;75:300–326.
   PubMed Web of Science ®Google Scholar
• McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14:1749–1758.
   PubMed Web of Science ®Google Scholar
• Siklos Prescribing Information. 2017 [cited 2018 Apr 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf
   Google Scholar
• Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–1048.
   PubMed Web of Science ®Google Scholar
• Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663–1672.
   PubMed Web of Science ®Google Scholar
• Opoka RO, Ndugwa CM, Latham TS, et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017;130:2585–2593.
   PubMed Web of Science ®Google Scholar
• Hankins JS, McCarville MB, Rankine-Mullings A, et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a Phase III international randomized clinical trial. Am J Hematol. 2015;90:1099–1105.
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387:661–670.
   PubMed Web of Science ®Google Scholar
• Berthaut I, Bachir D, Kotti S, et al. Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood. 2017;130:2354–2356.
   PubMed Web of Science ®Google Scholar
• FDA approves new treatment for sickle cell disease. FDA News Release. 2017 [cited 2018 Apr 29]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm566084.htm
   Google Scholar
• Zerez CR, Lachant NA, Lee SJ, et al. Decreased erythrocyte nicotinamide adenine dinucleotide redox potential and abnormal pyridine nucleotide content in sickle cell disease. Blood. 1988;71:512–515.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Zerez CR, Akiyama DS, et al. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol. 1998;58:117–121.
   PubMed Web of Science ®Google Scholar
• Rumen NM. Inhibition of sickling in erythrocytes by amino acids. Blood. 1975;45:45–48.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Matsui NM, Shen YM, et al. L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord. 2005;5:4.
   PubMedGoogle Scholar
• Burch JS, Marcero JR, Maschek JA, et al. Glutamine via alpha-ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis. Blood. 2018;132:987–998.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379:226–235.
   PubMed Web of Science ®Google Scholar
• Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013;368:1489–1497.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Brugnara C. Pathophysiological-based approaches to treatment of sickle cell disease. Annu Rev Med. 2003;54:89–112.
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006;27:204–210.
   PubMed Web of Science ®Google Scholar
• Rare diseases act, Pub. L. No. 107th Congress Public Law 280. 2002.
   Google Scholar
• Conran N, Rees DC. Prasugrel hydrochloride for the treatment of sickle cell disease. Expert Opin Investig Drugs. 2017;26:865–872.
   PubMed Web of Science ®Google Scholar
• Conran N. Prospects for early investigational therapies for sickle cell disease. Expert Opin Investig Drugs. 2015;24:595–602.
   PubMed Web of Science ®Google Scholar
• Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev. 2016;3:CD003426.
   PubMedGoogle Scholar
• Ataga KI, Stocker J. The trials and hopes for drug development in sickle cell disease. Br J Haematol. 2015;170:768–780.
   PubMed Web of Science ®Google Scholar
• Nottage K, Estepp J, Hankins JS. Future perspectives for the treatment of sickle cell anemia. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International Publishing AG; 2016. p. 399–429.
   Google Scholar
• Paikari A, Sheehan VA. Fetal haemoglobin induction in sickle cell disease. Br J Haematol. 2018;180:189–200.
   PubMed Web of Science ®Google Scholar
• Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017;129:2719–2726.
   PubMed Web of Science ®Google Scholar
• Telen MJ. Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors. Hematol Oncol Clin North Am. 2014;28:341–354.
   PubMed Web of Science ®Google Scholar
• Almeida CB, Kato GJ, Conran N. Inflammation and sickle cell anemia. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International Publishing AG; 2016. p. 177–211.
   Google Scholar
• Wandersee NJ, Hillery CA. Red blood cells and the vaso-occlusive process. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International Publishing AG; 2016. p. 49–74.
   Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–439.
   PubMed Web of Science ®Google Scholar
• Badaki-Makun O, Scott JP, Panepinto JA, et al. Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial. Pediatr Blood Cancer. 2014;61:1049–1054.
   PubMed Web of Science ®Google Scholar
• Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005;31:184–194.
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113:340–345.
   PubMed Web of Science ®Google Scholar
• Bennewitz MF, Jimenez MA, Vats R, et al. Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight. 2017;2:e89761.
   PubMed Web of Science ®Google Scholar
• Chweih C, Silva JAF, Ferreira Jr. WA, et al. Role for platelets in mediating neutrophil recruitment in tnf-α induced vaso-occlusive processes in animals with sickle cell anemia. Blood. 2017;130:540.
   Web of Science ®Google Scholar
• Ohno K, Tanaka H, Samata N, et al. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel. Thromb Res. 2014;134:889–894.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Zhou C, Small DS, et al. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013;75:1433–1444.
   PubMed Web of Science ®Google Scholar
• Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013;6:17.
   PubMed Web of Science ®Google Scholar
• Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374:625–635.
   PubMed Web of Science ®Google Scholar
• Oksenberg D, Dufu K, Patel MP, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;175:141–153.
   PubMed Web of Science ®Google Scholar
• Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett. 2017;8:321–326.
   PubMed Web of Science ®Google Scholar
• Dufu K, Patel M, Oksenberg D, et al. GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions. Clin Hemorheol Microcirc. 2018;70:95–105.
   PubMed Web of Science ®Google Scholar
• Dufu K, Oksenberg D. GBT440 reverses sickling of sickled red blood cells under hypoxic conditions in vitro. Hematol Rep. 2018;10:7419.
   PubMed Web of Science ®Google Scholar
• Lehrer-Graiwer J, Howard J, Hemmaway CJ, et al. GBT440, a potent anti-sickling hemoglobin modifier reduces hemolysis, improves anemia and nearly eliminates sickle cells in peripheral blood of patients with sickle cell disease. Blood. 2015;126:542.
   Web of Science ®Google Scholar
• Rademacher R, Hutchaleelaha A, Washington C, et al. Absorption, metabolism and excretion of gbt440, a novel hemoglobin s (Hbs) polymerization inhibitor for the treatment of sickle cell disease, in healthy male subjects. Blood. 2016;2016:2487.
   Google Scholar
• Ataga KI, Hoppe CC, Ware RE, et al. Novel trial design to evaluate oral voxelotor for the treatment of sickle cell disease: protocol of the phase 3 hemoglobin oxygen affinity modulation to inhibit HbS polymerization (HOPE) trial (GBT440-031). Hemasphere. 2018;2: PS1461:670: Abstract.
   Google Scholar
• Hoppe CC, Inati AC, Brown C, et al. Initial results from a cohort in a phase 2a study (GBT440-007) evaluating adolescents with sickle cell disease treated with multiple doses of GBT440, a HbS polymerization inhibitor. Blood. 2017;130:689. Abstract.
   Google Scholar
• Vichinsky E, Hoppe C, Howard J, et al. Results from part A of the hemoglobin oxygen affinity modulation to inhibit HbS polymerization (HOPE) trial (GBT440-031), a placebo-controlled randomized study evaluating voxelotor (GBT440) in adults and adolescents with sickle cell disease. 60th Annual Meeting of the American Society of Hematology, San Diego, USA. 2018: Abstract 505.
   Google Scholar
• website GBT. 2018 [cited 2018 6 11]. Available from: https://www.gbt.com/pipeline/sickle-cell-disease/
   Google Scholar
• Blyden G, Bridges KR, Bronte L. Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access. Am J Hematol. 2018;93:E188-E190.
   Web of Science ®Google Scholar
• Lehrer-Graiwer J, Howard J, Hemmaway CJ, et al. Long-term dosing in sickle cell disease subjects with GBT440, a novel HbS polymerization inhibitor. Blood. 2016;128:2488.
   Web of Science ®Google Scholar
• Hurst KV, O’Callaghan JM, Handa A. Quick reference guide to apixaban. Vasc Health Risk Manag. 2017;13:263–267.
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–829.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007;2007:91–96.
   Google Scholar
• Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016;30:245–256.
   PubMed Web of Science ®Google Scholar
• Yang ZW, Gebrewold A, Nowakowski M, et al. Mg(2+)-induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: role of NO. Am J Physiol Regul Integr Comp Physiol. 2000;278:R628–39.
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol. 2000;108:284–289.
   PubMed Web of Science ®Google Scholar
• Goldman RD, Mounstephen W, Kirby-Allen M, et al. Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease. Pediatrics. 2013;132:e1634–41.
   PubMed Web of Science ®Google Scholar
• Brousseau DC, Scott JP, Badaki-Makun O, et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015;126:1651–1657.
   PubMed Web of Science ®Google Scholar
• Dansdill D, Halandras PM, Beverly J, et al. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator. J Vasc Surg. 2018;67:294–299.
   PubMed Web of Science ®Google Scholar
• Adams-Graves P, Kedar A, Koshy M, et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood. 1997;90:2041–2046.
   PubMed Web of Science ®Google Scholar
• Carter C, Fisher TC, Hamai H, et al. Haemorheological effects of a nonionic copolymer surfactant (poloxamer 188). Clin Hemorhel. 1992;12:109.
   Google Scholar
• Sandor B, Marin M, Lapoumeroulie C, et al. Effects of poloxamer 188 on red blood cell membrane properties in sickle cell anaemia. Br J Haematol. 2016;173:145–149.
   PubMed Web of Science ®Google Scholar
• Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001;286:2099–2106.
   PubMed Web of Science ®Google Scholar
• Vepoloxamer does not meet primary endpoint in phase III study in patients with sickle cell disease. ASH Clinical News. 2016 Nov 1 [cited 2018 Apr 29].
   Google Scholar
• Chang J, Patton JT, Sarkar A, et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 2010;116:1779–1786.
   PubMed Web of Science ®Google Scholar
• McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015;107:331–339.
   PubMed Web of Science ®Google Scholar
• Wun T, Styles L, DeCastro L, et al. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS One. 2014;9:e101301.
   PubMed Web of Science ®Google Scholar
• Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125:2656–2664.
   PubMed Web of Science ®Google Scholar
• Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98:392–396.
   PubMed Web of Science ®Google Scholar
• Telen MJ, Batchvarova M, Shan S, et al. Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion. Br J Haematol. 2016;175:935–948.
   PubMed Web of Science ®Google Scholar
• Parr MK, Montacir O, Montacir H. Physicochemical characterization of biopharmaceuticals. J Pharm Biomed Anal. 2016;130:366–389.
   PubMed Web of Science ®Google Scholar
• Trosset JY, Carbonell P. Synthetic biology for pharmaceutical drug discovery. Drug Des Devel Ther. 2015;9:6285–6302.
   PubMed Web of Science ®Google Scholar
• Thein SL, Howard J. How I treat the older adult with sickle cell disease. Blood. 2018;132:1750–1760.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85:403–408.
   PubMed Web of Science ®Google Scholar